Chmp recommends approval of dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation

Chmp r ecommends a pproval of dupixent ® (dupilumab) for c hildren a ged 6 to 11 y ears with s evere a sthma with t ype 2 i nflammation
REGN Ratings Summary
REGN Quant Ranking